<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:podcast="https://podcastindex.org/namespace/1.0"
    xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"
    xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:spotify="http://www.spotify.com/ns/rss">
    <channel>
        <title>Trial Talks</title>
        <generator>Castos</generator>
        <atom:link href="https://feeds.castos.com/n6ox" rel="self" type="application/rss+xml" />
        <link>https://trial-talks.castos.com</link>
        <description>Welcome to the Trial Talks podcast – a thought-provoking series surrounding clinical trial research. We’ll be exploring current and future trends of the ever-changing clinical trial landscape as we discuss a variety of topics including virtual trials, patient centricity, novel and unique research, pandemic impact, and more. Join us and our expert guests on a journey through the evolution of clinical trials.</description>
        <lastBuildDate>Mon, 02 Aug 2021 04:24:00 +0000</lastBuildDate>
        <language>en</language>
        <copyright>© 2020</copyright>
        
        <spotify:limit recentCount="25" />
        
        <spotify:countryOfOrigin>
            US EU AU
        </spotify:countryOfOrigin>
                    <image>
                <url>https://episodes.castos.com/5ec69b8507eec2-49993548/images/TT-podcast.jpg</url>
                <title>Trial Talks</title>
                <link>https://trial-talks.castos.com</link>
            </image>
                <itunes:subtitle>Welcome to the Trial Talks podcast – a thought-provoking series surrounding clinical trial research. We’ll be exploring current and future trends of the ever-changing clinical trial landscape as we discuss a variety of topics including virtual trials, patient centricity, novel and unique research, pandemic impact, and more. Join us and our expert guests on a journey through the evolution of clinical trials.</itunes:subtitle>
        <itunes:author>Medrio</itunes:author>
        <itunes:type>episodic</itunes:type>
        <itunes:summary>Welcome to the Trial Talks podcast – a thought-provoking series surrounding clinical trial research. We’ll be exploring current and future trends of the ever-changing clinical trial landscape as we discuss a variety of topics including virtual trials, patient centricity, novel and unique research, pandemic impact, and more. Join us and our expert guests on a journey through the evolution of clinical trials.</itunes:summary>
        <itunes:owner>
            <itunes:name>Barbara Bliley</itunes:name>
            <itunes:email>marketing-accounts@medrio.com</itunes:email>
        </itunes:owner>
        <itunes:explicit>false</itunes:explicit>
                    <itunes:image href="https://episodes.castos.com/5ec69b8507eec2-49993548/images/TT-podcast.jpg"></itunes:image>
        
                                    <itunes:category text="Technology" />
                                                <itunes:category text="Health &amp; Fitness">
                                            <itunes:category text="Medicine" />
                                    </itunes:category>
                    
                    <itunes:new-feed-url>https://feeds.castos.com/n6ox</itunes:new-feed-url>
                
        
        <podcast:locked>yes</podcast:locked>
                                    <item>
                <title>
                    <![CDATA[Patient-Centricity: What Does It Mean and Where to Begin?]]>
                </title>
                <pubDate>Mon, 02 Aug 2021 04:24:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/patient-centricity-what-does-it-mean-and-where-to-begin</guid>
                                    <link>https://trial-talks.castos.com/episodes/patient-centricity-what-does-it-mean-and-where-to-begin</link>
                                <description>
                                            <![CDATA[<p><span style="font-weight:400;">With the rise of decentralized trials comes a focus on patient-centricity, but what does that look like holistically? Trishna Bharadia joins us to discuss the considerations you need to make when applying the patient perspective to clinical trial design. This episode will cover dynamic survey design, informed consent, patient diversity, and patient safety as they relate to achieving true patient-centricity in your studies. </span></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[With the rise of decentralized trials comes a focus on patient-centricity, but what does that look like holistically? Trishna Bharadia joins us to discuss the considerations you need to make when applying the patient perspective to clinical trial design. This episode will cover dynamic survey design, informed consent, patient diversity, and patient safety as they relate to achieving true patient-centricity in your studies. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Patient-Centricity: What Does It Mean and Where to Begin?]]>
                </itunes:title>
                                    <itunes:episode>5</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><span style="font-weight:400;">With the rise of decentralized trials comes a focus on patient-centricity, but what does that look like holistically? Trishna Bharadia joins us to discuss the considerations you need to make when applying the patient perspective to clinical trial design. This episode will cover dynamic survey design, informed consent, patient diversity, and patient safety as they relate to achieving true patient-centricity in your studies. </span></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-S02E05.mp3" length="40714956"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[With the rise of decentralized trials comes a focus on patient-centricity, but what does that look like holistically? Trishna Bharadia joins us to discuss the considerations you need to make when applying the patient perspective to clinical trial design. This episode will cover dynamic survey design, informed consent, patient diversity, and patient safety as they relate to achieving true patient-centricity in your studies. ]]>
                </itunes:summary>
                                                                            <itunes:duration>00:42:24</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Achieving Patient Centricity by Removing Barriers in the Clinical Trial Process]]>
                </title>
                <pubDate>Wed, 19 May 2021 20:25:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/achieving-patient-centricity-by-removing-barriers-in-the-clinical-trial-process</guid>
                                    <link>https://trial-talks.castos.com/episodes/achieving-patient-centricity-by-removing-barriers-in-the-clinical-trial-process</link>
                                <description>
                                            <![CDATA[<p>Constantly changing regulations and a multitude of new endpoints continue to keep clinical researchers on their toes. While these regulations and endpoints are designed to keep patients safe, they often create unintended barriers that keep patients out of clinical trials. In this episode, we discuss with Kafayat Babajide, Director of Patient Insights &amp; Experience with Johnson and Johnson, the ways in which a patient-centric approach can remove controllable barriers from the clinical trial process and strengthen your patient engagement.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Constantly changing regulations and a multitude of new endpoints continue to keep clinical researchers on their toes. While these regulations and endpoints are designed to keep patients safe, they often create unintended barriers that keep patients out of clinical trials. In this episode, we discuss with Kafayat Babajide, Director of Patient Insights & Experience with Johnson and Johnson, the ways in which a patient-centric approach can remove controllable barriers from the clinical trial process and strengthen your patient engagement.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Achieving Patient Centricity by Removing Barriers in the Clinical Trial Process]]>
                </itunes:title>
                                    <itunes:episode>4</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Constantly changing regulations and a multitude of new endpoints continue to keep clinical researchers on their toes. While these regulations and endpoints are designed to keep patients safe, they often create unintended barriers that keep patients out of clinical trials. In this episode, we discuss with Kafayat Babajide, Director of Patient Insights &amp; Experience with Johnson and Johnson, the ways in which a patient-centric approach can remove controllable barriers from the clinical trial process and strengthen your patient engagement.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-S02E04.mp3" length="21818595"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Constantly changing regulations and a multitude of new endpoints continue to keep clinical researchers on their toes. While these regulations and endpoints are designed to keep patients safe, they often create unintended barriers that keep patients out of clinical trials. In this episode, we discuss with Kafayat Babajide, Director of Patient Insights & Experience with Johnson and Johnson, the ways in which a patient-centric approach can remove controllable barriers from the clinical trial process and strengthen your patient engagement.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:22:43</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Patient Advocacy and Oncology: How A Community Cancer Network is Making a Difference]]>
                </title>
                <pubDate>Tue, 20 Apr 2021 14:48:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/patient-advocacy-and-oncology-how-a-community-cancer-network-is-making-a-difference</guid>
                                    <link>https://trial-talks.castos.com/episodes/patient-advocacy-and-oncology-how-a-community-cancer-network-is-making-a-difference</link>
                                <description>
                                            <![CDATA[<div class="podcast_excerpt_text">
<p>Approximately 39.5% of all men and women will be diagnosed with cancer at some point during their lifetimes, and yet only 8% of oncology patients participate in clinical trials. Many industry leaders think that a greater focus on patient advocacy could be the missing link.<br /><br />In this episode, Rose Gerber, Director of Patient Advocacy and Education at the Community Oncology Alliance – once a patient herself and now a dedicated advocate – will share her story and discuss how patient advocacy is helping to increase patient enrollment in clinical trials across every therapeutic area.</p>
</div>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[
Approximately 39.5% of all men and women will be diagnosed with cancer at some point during their lifetimes, and yet only 8% of oncology patients participate in clinical trials. Many industry leaders think that a greater focus on patient advocacy could be the missing link.In this episode, Rose Gerber, Director of Patient Advocacy and Education at the Community Oncology Alliance – once a patient herself and now a dedicated advocate – will share her story and discuss how patient advocacy is helping to increase patient enrollment in clinical trials across every therapeutic area.
]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Patient Advocacy and Oncology: How A Community Cancer Network is Making a Difference]]>
                </itunes:title>
                                    <itunes:episode>3</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<div class="podcast_excerpt_text">
<p>Approximately 39.5% of all men and women will be diagnosed with cancer at some point during their lifetimes, and yet only 8% of oncology patients participate in clinical trials. Many industry leaders think that a greater focus on patient advocacy could be the missing link.<br /><br />In this episode, Rose Gerber, Director of Patient Advocacy and Education at the Community Oncology Alliance – once a patient herself and now a dedicated advocate – will share her story and discuss how patient advocacy is helping to increase patient enrollment in clinical trials across every therapeutic area.</p>
</div>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-S02E03.mp3" length="37627078"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[
Approximately 39.5% of all men and women will be diagnosed with cancer at some point during their lifetimes, and yet only 8% of oncology patients participate in clinical trials. Many industry leaders think that a greater focus on patient advocacy could be the missing link.In this episode, Rose Gerber, Director of Patient Advocacy and Education at the Community Oncology Alliance – once a patient herself and now a dedicated advocate – will share her story and discuss how patient advocacy is helping to increase patient enrollment in clinical trials across every therapeutic area.
]]>
                </itunes:summary>
                                                                            <itunes:duration>00:39:11</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[EDC and RTSM: A Winning Combination]]>
                </title>
                <pubDate>Thu, 15 Apr 2021 13:59:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/edc-and-rtsm-a-winning-combination</guid>
                                    <link>https://trial-talks.castos.com/episodes/edc-and-rtsm-a-winning-combination</link>
                                <description>
                                            <![CDATA[<p><span style="font-weight:400;">Reducing the number of vendors you interact with allows you to not only achieve higher quality data, you can also spend more time focusing on what matters- the patients. Our fully integrated RTSM and EDC allows you to spend more time focused on your data and less on outside programmers and  vendors.  In this episode we will explore the value of a combined solution and what you can expect in return. </span></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Reducing the number of vendors you interact with allows you to not only achieve higher quality data, you can also spend more time focusing on what matters- the patients. Our fully integrated RTSM and EDC allows you to spend more time focused on your data and less on outside programmers and  vendors.  In this episode we will explore the value of a combined solution and what you can expect in return. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[EDC and RTSM: A Winning Combination]]>
                </itunes:title>
                                    <itunes:episode>1</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><span style="font-weight:400;">Reducing the number of vendors you interact with allows you to not only achieve higher quality data, you can also spend more time focusing on what matters- the patients. Our fully integrated RTSM and EDC allows you to spend more time focused on your data and less on outside programmers and  vendors.  In this episode we will explore the value of a combined solution and what you can expect in return. </span></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-7.mp3" length="21633861"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Reducing the number of vendors you interact with allows you to not only achieve higher quality data, you can also spend more time focusing on what matters- the patients. Our fully integrated RTSM and EDC allows you to spend more time focused on your data and less on outside programmers and  vendors.  In this episode we will explore the value of a combined solution and what you can expect in return. ]]>
                </itunes:summary>
                                                                            <itunes:duration>00:22:32</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[The Long Road to Achieving Health Equity]]>
                </title>
                <pubDate>Thu, 08 Apr 2021 12:27:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/the-long-road-to-achieving-health-equity-1</guid>
                                    <link>https://trial-talks.castos.com/episodes/the-long-road-to-achieving-health-equity-1</link>
                                <description>
                                            <![CDATA[<p>It’s no secret that the United States has documented disparities in morbidity and mortality rates among racial/ethnic minority groups and those of lower socioeconomic status. More recently we’ve seen a disproportionate amount of African Americans affected by COVID-19, but they have been underrepresented in clinical research. In this podcast we are joined by Kimberly Richardson, Patient Advocate and Cancer Survivor, to discuss how we can work towards achieving health equity in the United States, what steps can be taken today, and the impact this would have on clinical research and underserved communities.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[It’s no secret that the United States has documented disparities in morbidity and mortality rates among racial/ethnic minority groups and those of lower socioeconomic status. More recently we’ve seen a disproportionate amount of African Americans affected by COVID-19, but they have been underrepresented in clinical research. In this podcast we are joined by Kimberly Richardson, Patient Advocate and Cancer Survivor, to discuss how we can work towards achieving health equity in the United States, what steps can be taken today, and the impact this would have on clinical research and underserved communities.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[The Long Road to Achieving Health Equity]]>
                </itunes:title>
                                    <itunes:episode>2</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>It’s no secret that the United States has documented disparities in morbidity and mortality rates among racial/ethnic minority groups and those of lower socioeconomic status. More recently we’ve seen a disproportionate amount of African Americans affected by COVID-19, but they have been underrepresented in clinical research. In this podcast we are joined by Kimberly Richardson, Patient Advocate and Cancer Survivor, to discuss how we can work towards achieving health equity in the United States, what steps can be taken today, and the impact this would have on clinical research and underserved communities.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-S02E02.mp3" length="40025641"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[It’s no secret that the United States has documented disparities in morbidity and mortality rates among racial/ethnic minority groups and those of lower socioeconomic status. More recently we’ve seen a disproportionate amount of African Americans affected by COVID-19, but they have been underrepresented in clinical research. In this podcast we are joined by Kimberly Richardson, Patient Advocate and Cancer Survivor, to discuss how we can work towards achieving health equity in the United States, what steps can be taken today, and the impact this would have on clinical research and underserved communities.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:41:41</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Why Patient Advocacy Has Become Critical to Clinical Trials]]>
                </title>
                <pubDate>Fri, 26 Feb 2021 13:20:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/why-patient-advocacy-has-become-critical-to-clinical-trials</guid>
                                    <link>https://trial-talks.castos.com/episodes/why-patient-advocacy-has-become-critical-to-clinical-trials</link>
                                <description>
                                            <![CDATA[<p><span style="font-weight:400;">Patients are no longer passive research subjects, but rather being integrated into the research process from the start. Patient advocates help with such integrations, from protocol design through to clinical trial findings. It has been proven that designing clinical trials to meet the patient needs facilitates better patient adherence and reduces patient drop out rates. </span></p>
<p><span style="font-weight:400;">But more importantly, advocating for a patient is advocating for a human being, not a test subject. As clinical research evolves more emphasis has been placed on patient experience, rather than just data points. Listen to discover how a patient advocate, Susan Stein, MPH, advances patient care, brings the patient voice and insights into discussions and organizational decision making. </span></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Patients are no longer passive research subjects, but rather being integrated into the research process from the start. Patient advocates help with such integrations, from protocol design through to clinical trial findings. It has been proven that designing clinical trials to meet the patient needs facilitates better patient adherence and reduces patient drop out rates. 
But more importantly, advocating for a patient is advocating for a human being, not a test subject. As clinical research evolves more emphasis has been placed on patient experience, rather than just data points. Listen to discover how a patient advocate, Susan Stein, MPH, advances patient care, brings the patient voice and insights into discussions and organizational decision making. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Why Patient Advocacy Has Become Critical to Clinical Trials]]>
                </itunes:title>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><span style="font-weight:400;">Patients are no longer passive research subjects, but rather being integrated into the research process from the start. Patient advocates help with such integrations, from protocol design through to clinical trial findings. It has been proven that designing clinical trials to meet the patient needs facilitates better patient adherence and reduces patient drop out rates. </span></p>
<p><span style="font-weight:400;">But more importantly, advocating for a patient is advocating for a human being, not a test subject. As clinical research evolves more emphasis has been placed on patient experience, rather than just data points. Listen to discover how a patient advocate, Susan Stein, MPH, advances patient care, brings the patient voice and insights into discussions and organizational decision making. </span></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-6.mp3" length="16590662"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Patients are no longer passive research subjects, but rather being integrated into the research process from the start. Patient advocates help with such integrations, from protocol design through to clinical trial findings. It has been proven that designing clinical trials to meet the patient needs facilitates better patient adherence and reduces patient drop out rates. 
But more importantly, advocating for a patient is advocating for a human being, not a test subject. As clinical research evolves more emphasis has been placed on patient experience, rather than just data points. Listen to discover how a patient advocate, Susan Stein, MPH, advances patient care, brings the patient voice and insights into discussions and organizational decision making. ]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/5ec69b8507eec2-49993548/images/TrialTalksLogo-FullColor.jpg"></itunes:image>
                                                                            <itunes:duration>00:17:16</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Why Use an EDC for Animal Health Studies?]]>
                </title>
                <pubDate>Wed, 23 Dec 2020 19:08:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/why-use-an-edc-for-animal-health-studies</guid>
                                    <link>https://trial-talks.castos.com/episodes/why-use-an-edc-for-animal-health-studies</link>
                                <description>
                                            <![CDATA[<p><span style="font-weight:400;">ClinData is a leading South African CRO focused on Animal Health studies, they recently eradicated paper from 21 studies with plans to move more to electronic data capture going forward. In this podcast we’ll discuss how ClinData succeeded in making the switch from paper to EDC and the benefits of this change for animal health studies.</span></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[ClinData is a leading South African CRO focused on Animal Health studies, they recently eradicated paper from 21 studies with plans to move more to electronic data capture going forward. In this podcast we’ll discuss how ClinData succeeded in making the switch from paper to EDC and the benefits of this change for animal health studies.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Why Use an EDC for Animal Health Studies?]]>
                </itunes:title>
                                    <itunes:episode>6</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><span style="font-weight:400;">ClinData is a leading South African CRO focused on Animal Health studies, they recently eradicated paper from 21 studies with plans to move more to electronic data capture going forward. In this podcast we’ll discuss how ClinData succeeded in making the switch from paper to EDC and the benefits of this change for animal health studies.</span></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-05.mp3" length="6924610"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[ClinData is a leading South African CRO focused on Animal Health studies, they recently eradicated paper from 21 studies with plans to move more to electronic data capture going forward. In this podcast we’ll discuss how ClinData succeeded in making the switch from paper to EDC and the benefits of this change for animal health studies.]]>
                </itunes:summary>
                                                                            <itunes:duration>00:07:12</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Data Visualization - Making Data Comprehensible for Early Intervention]]>
                </title>
                <pubDate>Thu, 17 Sep 2020 15:33:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/data-visualization-making-data-comprehensible-for-early-intervention</guid>
                                    <link>https://trial-talks.castos.com/episodes/data-visualization-making-data-comprehensible-for-early-intervention</link>
                                <description>
                                            <![CDATA[<p><span style="font-weight:400;">Phastar and Medrio have been partnering together on trials for the past 3 years, culminating in a unique way to visualize clinical trial data. Through the use of Medrio’s API, Phastar has built a data visualization tool that reduces risk and allows for complete study oversight. In this podcast we’ll discuss the need for data visualization in clinical trials, how Phastar has continued their trials during a global pandemic, and what their thoughts are on the future of how we collect and view data. </span></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Phastar and Medrio have been partnering together on trials for the past 3 years, culminating in a unique way to visualize clinical trial data. Through the use of Medrio’s API, Phastar has built a data visualization tool that reduces risk and allows for complete study oversight. In this podcast we’ll discuss the need for data visualization in clinical trials, how Phastar has continued their trials during a global pandemic, and what their thoughts are on the future of how we collect and view data. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Data Visualization - Making Data Comprehensible for Early Intervention]]>
                </itunes:title>
                                    <itunes:episode>5</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><span style="font-weight:400;">Phastar and Medrio have been partnering together on trials for the past 3 years, culminating in a unique way to visualize clinical trial data. Through the use of Medrio’s API, Phastar has built a data visualization tool that reduces risk and allows for complete study oversight. In this podcast we’ll discuss the need for data visualization in clinical trials, how Phastar has continued their trials during a global pandemic, and what their thoughts are on the future of how we collect and view data. </span></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-04.mp3" length="20535901"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Phastar and Medrio have been partnering together on trials for the past 3 years, culminating in a unique way to visualize clinical trial data. Through the use of Medrio’s API, Phastar has built a data visualization tool that reduces risk and allows for complete study oversight. In this podcast we’ll discuss the need for data visualization in clinical trials, how Phastar has continued their trials during a global pandemic, and what their thoughts are on the future of how we collect and view data. ]]>
                </itunes:summary>
                                                                            <itunes:duration>00:21:23</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[What Does Clinical Trial Innovation Look Like?]]>
                </title>
                <pubDate>Fri, 14 Aug 2020 15:10:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/what-does-clinical-trial-innovation-look-like</guid>
                                    <link>https://trial-talks.castos.com/episodes/what-does-clinical-trial-innovation-look-like</link>
                                <description>
                                            <![CDATA[<p><span style="font-weight:400;">Quartesian and Medrio have had a solid partnership since 2010 and have partnered together in over 150 studies. In this podcast, we’ll discuss the foundation of our successful partnership, eSource, and the innovative ways we are collaborating with Quarteisan on a COVID-19 study currently underway. </span></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Quartesian and Medrio have had a solid partnership since 2010 and have partnered together in over 150 studies. In this podcast, we’ll discuss the foundation of our successful partnership, eSource, and the innovative ways we are collaborating with Quarteisan on a COVID-19 study currently underway. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[What Does Clinical Trial Innovation Look Like?]]>
                </itunes:title>
                                    <itunes:episode>4</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><span style="font-weight:400;">Quartesian and Medrio have had a solid partnership since 2010 and have partnered together in over 150 studies. In this podcast, we’ll discuss the foundation of our successful partnership, eSource, and the innovative ways we are collaborating with Quarteisan on a COVID-19 study currently underway. </span></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-E4-Quartesian.mp3" length="20274037"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Quartesian and Medrio have had a solid partnership since 2010 and have partnered together in over 150 studies. In this podcast, we’ll discuss the foundation of our successful partnership, eSource, and the innovative ways we are collaborating with Quarteisan on a COVID-19 study currently underway. ]]>
                </itunes:summary>
                                                                            <itunes:duration>00:21:07</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Stem-Cells: One Step Closer to a Cure | Hope Biosciences]]>
                </title>
                <pubDate>Mon, 27 Jul 2020 15:00:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/stem-cells-one-step-closer-to-a-cure-hope-biosciences</guid>
                                    <link>https://trial-talks.castos.com/episodes/stem-cells-one-step-closer-to-a-cure-hope-biosciences</link>
                                <description>
                                            <![CDATA[<p><span style="font-weight:400;">Welcome to the Trial Talks podcast, a thought-provoking show about clinical research. On this podcast, we will be exploring trends in the industry as well as the changing landscape, pandemic impact, various types of research, and more.</span></p>
<p><span style="font-weight:400;">Today, I’ll be talking with Donna Chang, the CEO and founder of Hope Biosciences. Hope Biosciences focuses on stem cell research to prevent disease and degeneration. In this episode we will be talking about the progress that has been made in the last decade, with regards to stem cell research. We’ll also be talking about stem cell research and COVID-19. </span></p>
<p><strong>Talking</strong> <strong>Points</strong><span style="font-weight:400;">:</span></p>
<ul>
<li style="font-weight:400;"><span style="font-weight:400;">What is Donna Chang’s background and how did Hope Biosciences start?</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">What has been happening in stem cell research in the last 5 - 10 years?</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">The Golden Age of Life Sciences</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">How this research applies to COVID-19</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">Getting studies up and running for COVID-19 (and other challenges)</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">Other studies and trials that Hope Biosciences is working on</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">The future trends of trials and the long term goals for Hope Biosciences</span></li>
</ul>
<p><strong>Resources</strong><span style="font-weight:400;">/</span><strong>Links</strong><span style="font-weight:400;">:</span></p>
<p><span style="font-weight:400;">Official website: </span><a href="http://www.hopebio.org"><span style="font-weight:400;">Hope Biosciences</span></a></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Welcome to the Trial Talks podcast, a thought-provoking show about clinical research. On this podcast, we will be exploring trends in the industry as well as the changing landscape, pandemic impact, various types of research, and more.
Today, I’ll be talking with Donna Chang, the CEO and founder of Hope Biosciences. Hope Biosciences focuses on stem cell research to prevent disease and degeneration. In this episode we will be talking about the progress that has been made in the last decade, with regards to stem cell research. We’ll also be talking about stem cell research and COVID-19. 
Talking Points:

What is Donna Chang’s background and how did Hope Biosciences start?
What has been happening in stem cell research in the last 5 - 10 years?
The Golden Age of Life Sciences
How this research applies to COVID-19
Getting studies up and running for COVID-19 (and other challenges)
Other studies and trials that Hope Biosciences is working on
The future trends of trials and the long term goals for Hope Biosciences

Resources/Links:
Official website: Hope Biosciences]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Stem-Cells: One Step Closer to a Cure | Hope Biosciences]]>
                </itunes:title>
                                    <itunes:episode>2</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><span style="font-weight:400;">Welcome to the Trial Talks podcast, a thought-provoking show about clinical research. On this podcast, we will be exploring trends in the industry as well as the changing landscape, pandemic impact, various types of research, and more.</span></p>
<p><span style="font-weight:400;">Today, I’ll be talking with Donna Chang, the CEO and founder of Hope Biosciences. Hope Biosciences focuses on stem cell research to prevent disease and degeneration. In this episode we will be talking about the progress that has been made in the last decade, with regards to stem cell research. We’ll also be talking about stem cell research and COVID-19. </span></p>
<p><strong>Talking</strong> <strong>Points</strong><span style="font-weight:400;">:</span></p>
<ul>
<li style="font-weight:400;"><span style="font-weight:400;">What is Donna Chang’s background and how did Hope Biosciences start?</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">What has been happening in stem cell research in the last 5 - 10 years?</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">The Golden Age of Life Sciences</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">How this research applies to COVID-19</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">Getting studies up and running for COVID-19 (and other challenges)</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">Other studies and trials that Hope Biosciences is working on</span></li>
<li style="font-weight:400;"><span style="font-weight:400;">The future trends of trials and the long term goals for Hope Biosciences</span></li>
</ul>
<p><strong>Resources</strong><span style="font-weight:400;">/</span><strong>Links</strong><span style="font-weight:400;">:</span></p>
<p><span style="font-weight:400;">Official website: </span><a href="http://www.hopebio.org"><span style="font-weight:400;">Hope Biosciences</span></a></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Trial-Talks-Hope-Bio.mp3" length="32512784"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Welcome to the Trial Talks podcast, a thought-provoking show about clinical research. On this podcast, we will be exploring trends in the industry as well as the changing landscape, pandemic impact, various types of research, and more.
Today, I’ll be talking with Donna Chang, the CEO and founder of Hope Biosciences. Hope Biosciences focuses on stem cell research to prevent disease and degeneration. In this episode we will be talking about the progress that has been made in the last decade, with regards to stem cell research. We’ll also be talking about stem cell research and COVID-19. 
Talking Points:

What is Donna Chang’s background and how did Hope Biosciences start?
What has been happening in stem cell research in the last 5 - 10 years?
The Golden Age of Life Sciences
How this research applies to COVID-19
Getting studies up and running for COVID-19 (and other challenges)
Other studies and trials that Hope Biosciences is working on
The future trends of trials and the long term goals for Hope Biosciences

Resources/Links:
Official website: Hope Biosciences]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/5ec69b8507eec2-49993548/images/TrialTalks-AppIcon-3000sq-Whiteback.jpg"></itunes:image>
                                                                            <itunes:duration>00:33:52</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Global Pandemic Challenges & Long-Term Strategies for Preparedness | Synteract]]>
                </title>
                <pubDate>Sun, 26 Jul 2020 19:56:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/global-pandemic-challenges-long-term-strategies-for-preparedness-synteract</guid>
                                    <link>https://trial-talks.castos.com/episodes/global-pandemic-challenges-long-term-strategies-for-preparedness-synteract</link>
                                <description>
                                            <![CDATA[<p><span style="font-weight:400;">Due to COVID-19 the clinical trial industry has been adopting advanced clinical trial technology at warp speed, but what does this mean for the future? What is a sustainable approach to ensure the industry does not face the same challenges and delays should we be impacted by another pandemic or global crisis? In this podcast we sit down with Mary Mattes, Senior Vice President of Global Operations at Synteract to discuss decentralization of clinical trials and a hybrid model. </span></p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Due to COVID-19 the clinical trial industry has been adopting advanced clinical trial technology at warp speed, but what does this mean for the future? What is a sustainable approach to ensure the industry does not face the same challenges and delays should we be impacted by another pandemic or global crisis? In this podcast we sit down with Mary Mattes, Senior Vice President of Global Operations at Synteract to discuss decentralization of clinical trials and a hybrid model. ]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Global Pandemic Challenges & Long-Term Strategies for Preparedness | Synteract]]>
                </itunes:title>
                                    <itunes:episode>3</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p><span style="font-weight:400;">Due to COVID-19 the clinical trial industry has been adopting advanced clinical trial technology at warp speed, but what does this mean for the future? What is a sustainable approach to ensure the industry does not face the same challenges and delays should we be impacted by another pandemic or global crisis? In this podcast we sit down with Mary Mattes, Senior Vice President of Global Operations at Synteract to discuss decentralization of clinical trials and a hybrid model. </span></p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-Synteract.mp3" length="24241274"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Due to COVID-19 the clinical trial industry has been adopting advanced clinical trial technology at warp speed, but what does this mean for the future? What is a sustainable approach to ensure the industry does not face the same challenges and delays should we be impacted by another pandemic or global crisis? In this podcast we sit down with Mary Mattes, Senior Vice President of Global Operations at Synteract to discuss decentralization of clinical trials and a hybrid model. ]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/5ec69b8507eec2-49993548/images/TrialTalks-AppIcon-3000sq-Whiteback.jpg"></itunes:image>
                                                                            <itunes:duration>00:20:12</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
                    <item>
                <title>
                    <![CDATA[Why Clinical Trials are Thriving in Australia & New Zealand | Avance Clinical]]>
                </title>
                <pubDate>Mon, 13 Jul 2020 22:12:00 +0000</pubDate>
                <dc:creator>Medrio</dc:creator>
                <guid isPermaLink="true">
                    https://trial-talks.castos.com/podcasts/8706/episodes/why-clinical-trials-are-thriving-in-australia-new-zealand-avance-clinical</guid>
                                    <link>https://trial-talks.castos.com/episodes/why-clinical-trials-are-thriving-in-australia-new-zealand-avance-clinical</link>
                                <description>
                                            <![CDATA[<p>Australia and New Zealand have not been impacted as much as North America and the EU with regards to COVID-19. For this reason, and their quick study-start timelines, this region could become very attractive to sponsors in the near future. In this podcast, Yvonne Lungershausen and Sandrien Louwaars discuss how Avance Clinical prepared for the pandemic, what tools they implemented that allowed trial continuation, and why clinical trials are currently thriving in the region.</p>]]>
                                    </description>
                <itunes:subtitle>
                    <![CDATA[Australia and New Zealand have not been impacted as much as North America and the EU with regards to COVID-19. For this reason, and their quick study-start timelines, this region could become very attractive to sponsors in the near future. In this podcast, Yvonne Lungershausen and Sandrien Louwaars discuss how Avance Clinical prepared for the pandemic, what tools they implemented that allowed trial continuation, and why clinical trials are currently thriving in the region.]]>
                </itunes:subtitle>
                                    <itunes:episodeType>full</itunes:episodeType>
                                <itunes:title>
                    <![CDATA[Why Clinical Trials are Thriving in Australia & New Zealand | Avance Clinical]]>
                </itunes:title>
                                    <itunes:episode>1</itunes:episode>
                                                <itunes:explicit>false</itunes:explicit>
                <content:encoded>
                    <![CDATA[<p>Australia and New Zealand have not been impacted as much as North America and the EU with regards to COVID-19. For this reason, and their quick study-start timelines, this region could become very attractive to sponsors in the near future. In this podcast, Yvonne Lungershausen and Sandrien Louwaars discuss how Avance Clinical prepared for the pandemic, what tools they implemented that allowed trial continuation, and why clinical trials are currently thriving in the region.</p>]]>
                </content:encoded>
                                    <enclosure url="https://episodes.castos.com/5ec69b8507eec2-49993548/Medrio-TrialTalks-Podcast-01.mp3" length="26173744"
                        type="audio/mpeg">
                    </enclosure>
                                <itunes:summary>
                    <![CDATA[Australia and New Zealand have not been impacted as much as North America and the EU with regards to COVID-19. For this reason, and their quick study-start timelines, this region could become very attractive to sponsors in the near future. In this podcast, Yvonne Lungershausen and Sandrien Louwaars discuss how Avance Clinical prepared for the pandemic, what tools they implemented that allowed trial continuation, and why clinical trials are currently thriving in the region.]]>
                </itunes:summary>
                                    <itunes:image href="https://episodes.castos.com/5ec69b8507eec2-49993548/images/TrialTalks-AppIcon-3000sq-Whiteback.jpg"></itunes:image>
                                                                            <itunes:duration>00:27:15</itunes:duration>
                                                    <itunes:author>
                    <![CDATA[Medrio]]>
                </itunes:author>
                            </item>
            </channel>
</rss>
